Asset profile
Nitrosomonas eutropha (B244)
Microbiome therapeutic
Evidence outlook · lead readout
NCT04490109 · Atopic Dermatitis, Pruritus
The completed lead evidence has the design features that historically survive confirmatory trials — randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT04490109: This was a randomized, quadruple-blind, vehicle-controlled trial with 547 enrolled participants, including approximately 165–174 evaluable participants per group. The primary clinical endpoint was met for both B244 doses, with significantly greater improvement in worst itch than vehicle.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.